VanEck Associates
PRCT icon

VanEck Associates’s Procept Biorobotics PRCT Stock Holding History

VanEck Associates’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,202
Closed -$205K – 1453
2026
Q1 		$205K Buy
8,202
+2,259
+38% +$63.7K ﹤0.01% 1263
2025
Q4 		$187K Buy
+5,943
New +$197K ﹤0.01% 1289

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VanEck Associates's PRCT Position: Q2 2026 in Review

VanEck Associates sold out of Procept Biorobotics (PRCT) in Q2 2026, closing a stake of 8,202 shares — an estimated $205K sold.

VanEck Associates first reported a position in PRCT in Q4 2025 and held it in 2 quarters. The position peaked at $205K in Q1 2026. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • VanEck Associates reported no remaining Procept Biorobotics position as of Q2 2026 after selling out during the quarter.
  • VanEck Associates sold 8,202 Procept Biorobotics shares in Q2 2026, an estimated $205K.
  • VanEck Associates first reported a position in Procept Biorobotics in Q4 2025 and held it in 2 quarters.
  • VanEck Associates's Procept Biorobotics position peaked at $205K in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.